
OZM-058
NCT02489006
JCP059
A Phase II, Open-Label, Randomized, Multi-Centre Study, of Neoadjuvant Olaparib in Patients with Platinum Sensitive Recurrent High Grade Serous Ovarian/Primary Peritoneal or Fallopian tube Cancer (The NEO trial)
Status:
Recruiting

II
Phase

2nd+
Line of Therapy

Relapsed / Recurrent / Refractory
Disease Stage

Biomarker(s)
N/A
Investigational
Product
Olaparib
VEGFR tyrosine kinase inhibitor (p.o.)
Treatment Arms
o Experimental: Olaparib Prior to Surgery, Chemotherapy/Olaparib Post Surgery
o Experimental: Olaparib Prior to Surgery and Post Surgery